# Collegium Pharmaceutical share price today (Collegium Pharmaceutical, Inc., COLL)

> Collegium Pharmaceutical, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. COLL · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/coll

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: $23.73 (−34.1% in a year)
- P/E: 16.9×, over 4.6 years
- Revenue (Jun 2026): $200 M (+6.3% on a year ago)
- Profit (Jun 2026): −$15.1 M (−225.6% on a year ago)
- Operating margin: 5.7% (−14.3 points on a year ago)
- ROE: 21%, FY25
- ROIC: 9.5%, against a 5.6% cost of capital: +3.9 points

The main question: yearly earnings per share moved −6.6% while the share price moved −34.1%. ## What is the Collegium Pharmaceutical share price today? Collegium Pharmaceutical, Inc.'s share price was $23.73 at the close on 3 November 2026. It has been falling for 8 weeks. That is 28.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $22 and $50, and at that close it sat 6% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 15 weeks running. Over the last 10 years the share price moved +86% while the S&P 500 moved +255%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 24 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Collegium Pharmaceutical pay? Collegium Pharmaceutical, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Collegium Pharmaceutical on? Collegium Pharmaceutical is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Collegium Pharmaceutical profitable? Collegium Pharmaceutical, Inc. posted a net loss of $15.1 M in the Jun 2026 quarter. Full-year FY25 profit was $62.9 M. Over 4 years profit has grown −3.2% a year on average. That loss is 7.5% of the quarter's revenue. The same quarter a year earlier earned $12.0 M. 1 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$15.1 M, −225.6% on a year earlier. For the full year, FY25 profit was $62.9 M (−9.1% on the year before). Why profit moved: revenue changed +6.3% on a year earlier and the margin moved −14.3 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +136.8% and revenue +14.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Collegium Pharmaceutical make, and is it growing? Collegium Pharmaceutical, Inc. reported $200 M of revenue in the Jun 2026 quarter, +6.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 29.6% a year on average. The last full year, FY25, came in at $781 M. The last four reported quarters add to $808 M. FY25 revenue was $781 M, +23.6% on the year before. Recent pace: the last four quarters grew +14.9% on average, against 29.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +14.3%, against +18.4% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +32.1%, against −30.7% a year (accelerating). ## How much of every $100 of sales does Collegium Pharmaceutical keep? Collegium Pharmaceutical, Inc.'s operating margin was 5.7% in the Jun 2026 quarter, 14.3 percentage points lower than the same quarter a year ago. Across 5 years it has been between 8.0% and 31.6%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −14.3 percentage points on the year while gross margin changed +1.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Collegium Pharmaceutical's profit turning into cash? Over the last 3 years, 449% of Collegium Pharmaceutical, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $329 M of operating cash against $62.9 M of profit. After $1.7 M of spending on assets, $328 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Collegium Pharmaceutical's cash go? Collegium Pharmaceutical, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $3.9 M on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $3.9 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Collegium Pharmaceutical's P/E ratio, and how does it compare with its own history? Collegium Pharmaceutical, Inc.'s P/E is 16.9×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −6.6% while the price moved −34.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +2.2% a year; about +83.2% a year came from earnings growth and about −81.0 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Collegium Pharmaceutical business getting better or worse? Collegium Pharmaceutical, Inc.'s business is turning around. Profit growth has swung from −53.0% at its low to +32.1%, rising from a low 4 quarters ago, with ROCE falling at 12.8%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does Collegium Pharmaceutical earn on its capital? Collegium Pharmaceutical, Inc. earned a ROE of 21% in FY25. That is up from a low of −13% in FY22. Its return on capital used (ROIC) is 3.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 8.1% net margin and 0.47× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 8.1% net margin × 0.47× asset turnover × 5.49× leverage (assets divided by equity) ≈ 20.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 9.5% − 5.6% = +3.9 percentage points. The 5.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 9.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 13.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Collegium Pharmaceutical have too much debt? Collegium Pharmaceutical, Inc. has total debt of $1.2 B against shareholder equity of $312 M as of Jun 2026, so its debt is 3.90× its equity. Year by year, that ratio went from 1.28 in FY21 to 3.10 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Collegium Pharmaceutical shareholding pattern? 18.1% of Collegium Pharmaceutical, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Collegium Pharmaceutical from balance-sheet trouble? For Collegium Pharmaceutical, Inc., the Z-score is 0.99. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.99 is inside the danger zone, so the balance sheet is a real risk. ## How does Collegium Pharmaceutical rank in its industry? There is no score against its industry: Collegium Pharmaceutical, Inc. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Collegium Pharmaceutical compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Collegium Pharmaceutical in size? Collegium Pharmaceutical is the 35th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Amphastar Pharmaceuticals, Inc., Harrow, Inc. and Esperion Therapeutics, Inc. Just below it: Ironwood Pharmaceuticals, Inc., Evotec SE and Aquestive Therapeutics, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Amphastar Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amph) $1.2 billion
2. [Harrow, Inc.](https://www.sectoralpha.in/us/stocks/hrow) $1.1 billion
3. [Esperion Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/espr) $819 million
4. Collegium Pharmaceutical, Inc. $773 million
5. [Ironwood Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/irwd) $578 million
6. [Evotec SE](https://www.sectoralpha.in/us/stocks/evo) $569 million
7. [Aquestive Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/aqst) $487 million

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Azul S.A.](https://www.sectoralpha.in/us/stocks/azul) $773 million · Airlines
2. [Phreesia, Inc.](https://www.sectoralpha.in/us/stocks/phr) $772 million · Health Information Services
3. Collegium Pharmaceutical, Inc. $771 million
4. [Playtika Holding Corp.](https://www.sectoralpha.in/us/stocks/pltk) $770 million · Electronic Gaming & Multimedia
5. [Westlake Chemical Partners LP](https://www.sectoralpha.in/us/stocks/wlkp) $769 million · Chemicals

## What else do people ask about Collegium Pharmaceutical? ### What were Collegium Pharmaceutical's latest quarterly results? Collegium Pharmaceutical, Inc. reported revenue of $200 M and a net loss of $15.1 M for the Jun 2026 quarter. Revenue rose 6.3% and profit fell 225.6% compared with a year earlier. Earnings per share were −$0.46. The operating margin was 5.7%, 14.3 percentage points lower than a year earlier (as of 3 November 2026). ### What is Collegium Pharmaceutical's market cap? Collegium Pharmaceutical, Inc.'s market capitalisation is $773 M at a stock price of $23.73. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Collegium Pharmaceutical performing? Collegium Pharmaceutical, Inc.'s share price has been falling for 8 weeks. In its latest quarter, revenue rose 6.3% and profit fell 225.6% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 15 weeks running (as of 3 November 2026). ### Will Collegium Pharmaceutical's stock price go up? This page does not forecast Collegium Pharmaceutical, Inc.'s stock price. What it shows instead: the stock price is $23.73, and it has been falling for 8 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Collegium Pharmaceutical in its business cycle? Collegium Pharmaceutical, Inc.'s FY25 operating margin was 24.7%, against a 5-year range of 8.0% to 31.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 5.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Collegium Pharmaceutical story? The main question: yearly earnings per share moved −6.6% while the share price moved −34.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Collegium Pharmaceutical a stock worth studying right now? What the numbers show: Collegium Pharmaceutical, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.